Personalis
Personalis Inc is an American multinational cancer genomics and precision medicine enterprise specializing in the research, development, clinical analysis, and global wholesale distribution of advanced genomic sequencing services, tumor immune profiling platforms, and comprehensive diagnostic assays designed to guide personalized immunotherapy and cancer treatment selection for patients, biopharmaceutical developers, and clinical researchers across the United States and international medical markets. Operating advanced clinical-grade genomic sequencing laboratories, the company transforms the understanding of cancer biology through deep data insights. Its core business operations encompass clinical molecular diagnostic sequencing, tumor profiling research, bioinformatics analysis, and pharmaceutical precision medicine partnerships. Revenue is derived primarily from commercial clinical diagnostic billings, biopharmaceutical R&D partnership agreements, and genomic data service fees. Personalis holds a leading market position in comprehensive cancer genomics and immunotherapy biomarker development. The company is headquartered in Fremont, California, United States, and its common stock trades on the Nasdaq Global Market under the ticker PSNL.
2 of the funds FundTelligence covers report a position in Personalis.
- Legal name
- Personalis Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
- Exposure themes
- Cancer Profiling, Molecular Diagnostics, Precision Medicine & Genomics
Funds holding Personalis
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.11 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)